MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.

肝硬化性乳糜性腹水：应筛查其他导致乳糜性腹水的原因，并进行相应的病因治疗。需进行饮食调整，给予低盐、低脂、中链甘油三酯高蛋白饮食，减少乳糜的产生。特利加压素及生长抑素类似物有助于缓解乳糜性腹水，但目前尚缺乏大样本研究的结果。TIPS也可缓解乳糜性腹水 ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update. "The Mirum team executed ...